BRIEF—Ophthotech mutates into Iveric

US ophthalmology specialist Ophthotech Corporation has given itself a new name to reflect its change to becoming a company focused on discovering and developing gene therapies to treat orphan inherited retinal diseases for which there are no other treatments.

The company now calls itself Iveric Bio and will trade on the Nasdaq Global Select Market under the ticker symbol ISEE.

Kourous Rezaei, chief medical officer of Iveric, said: “We look forward to the exciting opportunities that lie ahead. Our clinical therapeutic programs continue to remain on track, with clinical data expected by the end of 2019 and 2020 for these programs. If data are positive, we may seek partnership opportunities for future clinical development.”